who has already announced that it is retrenching, may put the kibosh on the expense of the introduction of a new, unproven line by their subsidiary STP?
Perhaps the reluctance of Howard to disclose details is that this deal is not quite as "writ in stone" as he would like folks to believe.
News 
Market Data 
Discover 
AI
